Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 2024 Superconvergence BioRevolution Series: A Blockbuster Gene Therapy? By: ETF Trends August 31, 2024 at 07:30 AM EDT By Christopher Gannatti, CFA, Global Head of Research Key Takeaways The biotechnology sector has not seen a sustained rally in 2024 despite initial optimism and ongoing progress. Sarepta Therapeutics’ Elevidys, a $3.2 million gene therapy for Duchenne muscular dystrophy, received expanded FDA approval in June 2024, with positive indications on insurance coverage being a key [...] The post 2024 Superconvergence BioRevolution Series: A Blockbuster Gene Therapy? appeared first on ETF Trends . Read More >> Related Stocks: WisdomTree BioRevolution Fund Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
2024 Superconvergence BioRevolution Series: A Blockbuster Gene Therapy? By: ETF Trends August 31, 2024 at 07:30 AM EDT By Christopher Gannatti, CFA, Global Head of Research Key Takeaways The biotechnology sector has not seen a sustained rally in 2024 despite initial optimism and ongoing progress. Sarepta Therapeutics’ Elevidys, a $3.2 million gene therapy for Duchenne muscular dystrophy, received expanded FDA approval in June 2024, with positive indications on insurance coverage being a key [...] The post 2024 Superconvergence BioRevolution Series: A Blockbuster Gene Therapy? appeared first on ETF Trends . Read More >> Related Stocks: WisdomTree BioRevolution Fund
